Irna compositions and methods for silencing angiotensinogen (agt)
AssigneeAlnylam Pharmaceuticals, Inc.
InventorsPaul Nioi, James D. McIninch, Mark K. Schlegel, Adam Castoreno, Joseph Barry
Life of this patent
Estimating the term…
Abstract
The present invention relates to RNAi agents, e.g., double stranded RNA (dsRNA) agents, targeting an angiotensinogen (AGT) gene. The invention also relates to methods of using such RNAi agents to inhibit expression of an AGT gene and to methods of preventing and treating an AGT-associated disorder, e.g., hypertension.
Claims81
A double stranded ribonucleic acid (dsRNA) agent for inhibiting expression of angiotensinogen (AGT) in a cell, wherein the dsRNA agent comprises a sense strand and an antisense strand forming a double stranded region, wherein the antisense strand comprises a region of complementarity to an mRNA encoding AGT, and wherein the region of complementarity comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from any one of the antisense nucleotide sequences in any one of Tables 2-7.
Dependencies are inferred from the claim text.